Diablo Clinical ResearchWalnut Creek, California, United States
Disclosure(s): No financial relationships to disclose
571 - Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Saturday, October 19, 20241:45 PM – 2:03 PM US PT